Cheng Guangqing, Yan Xiaoni, Wang Fengmeng, Chen Chao
Department of Gerontology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, Shandong, China.
Department of Rehabilitation, Zibo TCM-Integrated Hospital, Zibo 255026, Shandong, China.
Evid Based Complement Alternat Med. 2021 Oct 31;2021:2739092. doi: 10.1155/2021/2739092. eCollection 2021.
Carotid atherosclerosis (CAS) is a common disease which seriously threatens the health of senile patients. The studies have indicated that traditional Chinese medicine (TCM) may effectively improve the symptom of CAS, while the therapeutic effect of Huayu Tongmai decoction on CAS remains unclear. Thus, this study aimed to explore the correlation between traditional Chinese medicine Huayu Tongmai decoction intervention and prognosis indexes of patients with CAS.
Ninety CAS patients admitted to from September 2018 to September 2020 were selected as the research object and randomly divided into the control group and the observation group according to the male-female ratio of 1 : 1. Patients in the control group accepted the atorvastatin intervention, and on this basis, patients in the observation group were further intervened with TCM Huayu Tongmai decoction. Before and after treatment, patients' levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were measured by the enzyme photometric colorimetry; hypersensitive c-reactive protein (hs-CRP) levels were measured by the ELISA method; nitric oxide (NO) levels were measured by the nitrate reductase assay and endothelin-1 (ET-1) levels were measured by radioimmunoassay; and the right and left carotid internal diameter (CAD), intima-media thickness (IMT), and plaque volume were measured by carotid ultrasonography.
The TC, TG, and LDL-C levels significantly decreased in patients compared to those before intervention; compared with the control group, patients who accepted Huayu Tongmai decoction combined with atorvastatin saw more significant improvement in their blood lipid indexes ( < 0.01); after intervention, patients' hs-CRP and ET-1 levels dropped significantly while the NO level rose remarkably, and between the two groups, the improvement in levels of hs-CRP, ET-1, and NO of patients in the observation group was significantly better ( < 0.01); it was concluded from the imaging diagnosis results that compared with using atorvastatin alone, the combined intervention could better improve patients' CAD, IMT, and plaque volume.
Huayu Tongmai decoction can effectively improve patients' blood lipid, reduce inflammatory response, enhance levels of relevant regulatory factors of CAS, and alleviate the symptoms.
颈动脉粥样硬化(CAS)是一种严重威胁老年患者健康的常见疾病。研究表明,中药可能有效改善CAS症状,而化瘀通脉汤对CAS的治疗效果尚不清楚。因此,本研究旨在探讨中药化瘀通脉汤干预与CAS患者预后指标之间的相关性。
选取2018年9月至2020年9月收治的90例CAS患者作为研究对象,按照男女比例1∶1随机分为对照组和观察组。对照组患者接受阿托伐他汀干预,在此基础上,观察组患者加用中药化瘀通脉汤进一步干预。治疗前后,采用酶比色法测定患者总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)水平;采用酶联免疫吸附测定法测定超敏C反应蛋白(hs-CRP)水平;采用硝酸还原酶法测定一氧化氮(NO)水平,采用放射免疫分析法测定内皮素-1(ET-1)水平;采用颈动脉超声测量左右颈总动脉内径(CAD)、内膜中层厚度(IMT)和斑块体积。
与干预前相比,患者的TC、TG和LDL-C水平显著降低;与对照组相比,接受化瘀通脉汤联合阿托伐他汀治疗的患者血脂指标改善更显著(P<0.01);干预后,患者的hs-CRP和ET-1水平显著下降,而NO水平显著上升,两组间,观察组患者hs-CRP、ET-1和NO水平的改善明显更好(P<0.01);影像学诊断结果显示,与单独使用阿托伐他汀相比,联合干预能更好地改善患者的CAD、IMT和斑块体积。
化瘀通脉汤可有效改善患者血脂,减轻炎症反应,提高CAS相关调节因子水平,缓解症状。